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Abstract 
Angiomatoid fibrous histiocytoma (AFH) is
a rare disease that is often misdiagnosed ini-
tially. Patients can present with a clinical pic-
ture concerning for other diseases, and patho-
logic review is not always revealing. Molecular
diagnostics are increasingly being utilized to
detect  gene  fusions  characteristic  for  AFH.
Surgery  remains  the  mainstay  of  manage-
ment, and can effectively control local recur-
rences and metastases. Herein we describe a
case report of a 25-year-old gentleman whose
presentation  was  concerning  for  lymphoma.
Subsequently we review of the relevant litera-
ture. 
Introduction
Angiomatoid fibrous histiocytoma (AFH) is
a rare soft tissue tumor that is found primari-
ly in the extremities of children.
1 It is normal-
ly difficult to make a pre-operative diagnosis
of AFH; more and more, molecular diagnostics
are being utilized to establish the diagnosis in
situations where the pathology is not conclu-
sive. We present a case of a 25-year-old gentle-
man  whose  presentation  was  initially  con-
cerning  for  lymphoma.  The  diagnosis  was
established  upon  pathologic  review  with
immunohistochemistry.  Following  the  case
report we provide a review the literature.
Case Report
A 25-year-old gentleman presented to our
institution for evaluation of night sweats and
fatigue. The night sweats started 18 months
prior to presentation and became drenching
during  the  preceding  two  months.  He  felt
fatigued  throughout  the  day  and  noticed
weight  loss  despite  a  normal  appetite.  He
denied fever, chills or pruritus and was not on
any  medications.  He  was  of  Northern  and
Eastern European decent. His family history
was  significant  for  coronary  artery  disease
and breast cancer.
The  patient  lived  with  his  parents  and
worked as a chef. He had a 10 pack-year histo-
ry of smoking but had quit recently. He contin-
ued to chew tobacco. Two years prior to pres-
entation he visited many countries in Western
Europe. On examination he was afebrile with
a  normal  blood  pressure  and  regular  pulse.
There was a large, fixed, non-tender mass in
his left axilla. The rest of the examination was
otherwise normal. Laboratory studies revealed
a microcytic anemia with a hemoglobin of 10.6
g/dL (adult males 13.5-17.5 g/dL) and a mean
corpuscular volume of 77.9 fL (80-100 fL). His
ferritin was 499 mg/L (males 24-336 mg/L) and
erythrocyte sedimentation rate 126 mm/hr (0-
22 mm in one hour). Peripheral blood smear
demonstrated rouleaux formation, anisocyto-
sis, microcytosis and hypochromic red blood
cells. Flow cytometry of peripheral blood did
not demonstrate any monotypic B-cell popula-
tion or increase in blast cells. There was no
monoclonal protein on serum electrophoresis.
Tests for hepatitis A, B and C, HIV 1 and 2 and
brucellosis were negative. Fecal occult blood
testing was negative.
A  CT  chest  showed  an  indeterminate
4.3ﾥ2.7  cm  soft  tissue  mass  with  multiple
prominent  left  axillary  lymph  nodes,  the
largest having an 8 mm diameter. Magnetic
resonance  imaging  (MRI)  revealed  a
5.3ﾥ4.6ﾥ3.6 cm solid, heterogenously enhanc-
ing intermuscular mass, in the superior por-
tion of the left axilla, inferior to the gleno-
humeral joint (Figure 1). The mass abutted
the left axillary artery and vein, and encased
some of the brachial plexus cords. The appear-
ance  was  suggestive  of  an  extra-abdominal
desmoid  tumor.  An  ultrasound-guided  fine
needle  aspiration  was  pursued.  The  smears
showed atypical spindle cell proliferation sus-
picious for sarcoma, but they were not diag-
nostic. Axillary fluid cultures for aerobic and
anaerobic  bacteria,  mycobacteria  and  fungi
demonstrated no growth. An acid fast smear of
axillary fluid was negative.
An  open  biopsy  was  performed  and  a
3.0ﾥ1.7ﾥ0.8 cm aggregate of hemorrhagic soft
tissue was removed. The frozen section was
read  as  an  undifferentiated  neoplasm,  and
metastatic melanoma and rhabdomyosarcoma
were on the pathologic differential diagnosis.
Immunoperoxidase  studies  performed  on
paraffin sections demonstrated that the neo-
plastic cells were positive for vimentin, EMA
(focal) and CD68. These cells were negative
for S100, melan A, HMB45, myogenin, desmin,
smooth muscle actin and keratin. The diagno-
sis of angiomatoid fibrous histiocytoma was
made based on these studies.
Treatment options were discussed with the
patient.  He  elected  to  pursue  preoperative
radiation followed by definitive resection. He
received 50 Gy in 25 fractions to the tumor.
One month later, the superior aspect of the
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Figure 1. MRI revealed a 5.3ﾥ4.6ﾥ3.6 cm
solid,  heterogenously  enhancing  mass  in
the superior portion of the left axilla, infe-
rior  to  the  glenohumeral  joint.  A  cystic
component is best seen in the right upper
panel.
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tumor was dissected from the brachial plexus
and the axillary artery and vein, but the tho-
racodorsal  artery  and  vein  were  sacrificed.
The margins were negative on visual inspec-
tion, but the deep margin was negative only
by 1 mm. It was elected to boost the tumor
bed with intraoperative radiation therapy and
he received 1000 cGy with 6 MeV electrons
calculated at the 90% isodose depth to the
tumor bed. 
A  white-tan,  lobulated,  hemorrhagic,  firm
mass measuring 6.5ﾥ4.3ﾥ3.2 cm was resected
(Figure 2). Pathology revealed an angiomatoid
fibrous  histiocytoma.  Minimal  treatment
effect  was  present.  Eight  regional  axillary
lymph nodes were negative for tumor.  All sur-
gical  resection  margins  were  negative  for
tumor and the minimum tumor free margin
was less than 0.1 cm. 
The  neoplastic  cells  were  positive  for
desmin and negative for smooth muscle actin,
myogenin,  EMA  and  S100  (Figure  3).
Chromosome  analysis  revealed  several  non-
clonal  structural  anomalies  in  each  meta-
phase,  likely  due  to  pre-operative  radiation
therapy.
An MRI obtained three months post-opera-
tively  revealed  a  fluid  collection  within  the
axilla but no discrete enhancing mass to sug-
gest recurrence.
Discussion
Angiomatoid  fibrous  histiocytoma  (AFH)
was first described in 1979 in a case series of
41 patients.
1 It typically occurs in the extremi-
ties of children and young adults, but patients
aged even 71 years have also been reported.
2
Most of the time, AFH presents as a superfi-
cial subcutaneous mass and is thought to rep-
resent lymphadenopathy, or a benign cyst on
clinical examination.
1,3 Patients may also pres-
ent with fever and weight loss while anemia
and polyclonal hypergammaglobulinemia are
common laboratory findings.
1,3,4 Imaging stud-
ies  alone,  cannot  differentiate  AFH  from
malignant  fibrous  histiocytoma,  sarcoma  or
other  tumors.
5 Cystic  components  seen  on
magnetic resonance imaging were correlated
with hemorrhage in a case report.
6
Pathologically,  AFH  usually  demonstrates
four features: a fibrous pseudocapsule, a round
or spindle fibrohistiocytic cell proliferation, a
pseudoangiomatous pattern and a plasmalym-
phocytic infiltrate.
7 Sometimes the round cells
and CD99 or desmin positivity raise concern
for  Ewing’s  sarcoma  or  rhabdomyosarcoma,
respectively.  In  one  immunohistochemical
review,  all  cases  of  AFH  were  positive  for
vimentin, most were positive for calponin, and
more than half were positive for desmin. There
were also some samples that were positive for
CD99, SMA or MSA, but no samples were posi-
tive  for  myoglobin,  S100,  CD21,  or  CD35.
2
Fluorescent in situ hybridization (FISH) and
reverse  transcription-polymerase  chain  reac-
tion have been used more recently to demon-
strate that EWSR1-CREB1 is the predominant
fusion gene in AFH, but EWSR1-ATF1 and FUS-
ATF1 gene  rearrangements  have  also  been
described.
8-13Sometimes FISH has been used to
confirm cases of AFH with pleomorphic fea-
tures that were difficult to diagnose with opti-
cal  morphology  and  immunohistochemistry.
14
The  EWSR1-ATF1 gene  arrangement  is  also
described in another clinically distinct entity,
clear cell sarcoma.
15
In the initial series of 41 patients, 24 were
available  for  follow-up.  Among  these  24
patients, 11 had local recurrences and 5 had
metastatic  disease.  The  name  angiomatoid
malignant fibrous histiocytoma (AMFH) was
given based on the observed metastatic poten-
tial.
1 Eleven years later, another series of 108
patients  was  presented,  of  whom  94  were
available for follow-up. Of those patients, 11
had  recurred  locally  and  were  adequately
treated  with  wide  local  excisions.  Five
patients  were  found  or  suspected  to  have
metastatic disease on follow-up.
3 AMFH was
considered to be a fibrohistiocytic malignancy
of  intermediate  malignancy  based  on  this
larger  series  and  was  renamed  AFH.
Recurrence  in  patients  with  AFH  has  been
associated with location in the head or neck,
ostensibly due to the difficulty with complete
excision in this area, and with an irregular
tumor border
3 that makes complete resection
also difficult.
Surgery alone with a wide local excision can
be utilized to establish local control; however,
in cases where a marginal excision is planned,
radiation therapy should be utilized to maxi-
mize  control.  In  this  setting,  pre-operative
radiation is preferred to post-operative radia-
tion, as the latter implies greater toxicity.
16
It  is  important  to  distinguish  AFH  from
malignant fibrous histiocytoma,
17 Ewing’s sar-
coma and rhabdomyosarcoma, due to the dif-
ferences in the potential for local recurrence
and metastasis and management of these dis-
eases.
In the case we describe, the initial presen-
tation was concerning for lymphoma due to
the palpable axillary mass, anemia and histo-
ry of weight loss and night sweats. This pres-
entation  is  not  unusual  for  patients  with
AFH.
1-4  The imaging studies we obtained were
not  diagnostic,  but  pathologic  review  with
immunohistochemistry led to the diagnosis of
AFH. Although chromosomal analysis was per-
formed, neither FISH nor RT-PCR was used to
detect  the  fusion  transcripts  seen  in  AFH.
Although surgery is often curative, radiation
therapy was utilized to maximize control due
to the narrow surgical margins.
Case Report
Figure 2. At surgery a white-tan, lobulat-
ed, hemorrhagic and focally necrotic firm
mass  measuring  6.5ﾥ4.3ﾥ3.2  cm  was
removed for pathologic review.
Figure 3. Pathologic review revealed multi-
ple bland, vesicular nuclei (upper image).
There was also a thick fibrous pseudocap-
sule  and  a  lymphoplasmacytic  infiltrate
(not shown). The neoplastic cells were pos-
itive for desmin (lower image).
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Conclusions
AFH is a rare disease that is often misdiag-
nosed  initially.  Patients  can  present  with  a
clinical picture suggestive of other diseases,
such  as  lymphoma  as  in  our  patient.
Additionally, pathologic review can be concern-
ing for a sarcoma with more malignant poten-
tial.  Although  thorough  pathologic  review  is
critical for the diagnosis, techniques such as
FISH have been used to confirm cases with
pleomorphic  features.  AFH  can  recur  locally,
but most of these patients do well with wide
local excisions alone, if a wide surgical margin
is possible. Radiotherapy may be utilized when
wide excision margins are not feasible. AFH
does have low potential for metastasis, but sur-
gery can be effective in these cases as well.
Our patient did well following his procedure
without evidence of recurrence at follow-up.
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